Advisors Asset Management Inc. Cuts Holdings in Repligen Corporation $RGEN

Advisors Asset Management Inc. lowered its position in Repligen Corporation (NASDAQ:RGEN) by 20.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,826 shares of the biotechnology company’s stock after selling 2,312 shares during the period. Advisors Asset Management Inc.’s holdings in Repligen were worth $1,098,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Twin Tree Management LP acquired a new position in Repligen in the 1st quarter worth about $29,000. Hantz Financial Services Inc. grew its holdings in Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the period. Center for Financial Planning Inc. increased its position in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 126 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Repligen during the 2nd quarter worth approximately $104,000. Finally, Hilltop National Bank acquired a new position in shares of Repligen during the 2nd quarter worth approximately $147,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 20,000 shares of the firm’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the completion of the sale, the director directly owned 80,743 shares in the company, valued at approximately $12,483,675.23. This trade represents a 19.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO James Bylund sold 2,191 shares of Repligen stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total transaction of $331,301.11. Following the transaction, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 49,382 shares of company stock valued at $7,676,802 over the last ninety days. Corporate insiders own 1.20% of the company’s stock.

Repligen Trading Down 0.0%

RGEN opened at $171.11 on Monday. The firm has a market capitalization of $9.63 billion, a price-to-earnings ratio of 8,559.78, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. The company’s 50 day simple moving average is $149.72 and its two-hundred day simple moving average is $131.80. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The business had revenue of $188.81 million during the quarter, compared to analyst estimates of $181.23 million. During the same period in the prior year, the business earned $0.43 earnings per share. The business’s revenue was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on RGEN. HSBC began coverage on shares of Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price target for the company. Hsbc Global Res upgraded shares of Repligen to a “strong-buy” rating in a research report on Wednesday, October 1st. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Wednesday, October 29th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $173.85.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.